Notice
16 Jun 2025
regulatory compliance, health care, fda, drug development, pharmaceutical industry, patent extension, briumvi
💊FDA Notice on BRIUMVI Patent Extension Implications
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIUMVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More